Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 3/20 | 0.34 |
| ▸ | THRB | P10828 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316894 | 1.00 | THRA (0.34) | THRATHRBMEN1KMT2ANPC1 | |
| SCHEMBL17141150 | 0.86 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL3319502 | 0.86 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL3319508 | 0.86 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL2199749 | 0.85 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL2199746 | 0.85 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL3313883 | 0.84 | NPC1 (0.33) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL3313889 | 0.84 | NPC1 (0.33) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL16116237 | 0.83 | ALDH1A1 (0.38) | KMT2ANPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL3319836 | 0.83 | ALDH1A1 (0.38) | KMT2ANPC1RAB9ASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | THRA 3964/4885THRB 2611/4885MEN1 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.